GO:0008286 insulin receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008286 describes the molecular signal cascade triggered when insulin binds the insulin receptor (INSR), a receptor tyrosine kinase.
• The pathway controls glucose uptake, glycogen synthesis, lipogenesis, protein synthesis, and cell survival, and its dysfunction underlies insulin resistance and type 2 diabetes.
• Core nodes include INSR, IRS1/IRS2, PI3K (PIK3CA/PIK3R1), AKT1/2, and the MAPK cascade (GRB2, SOS1, HRAS, MAP2K1, MAPK1/3).
• The pathway is evolutionarily conserved; the Caenorhabditis elegans ortholog daf-2 regulates longevity and diapause, linking insulin signaling to aging.
• Insulin receptor isoforms (IR-A, IR-B) and IGF-like receptors diversify signaling outputs relevant to cancer and chemoresistance.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of pathway genes in metabolic and oncogenic contexts.
Description
The insulin receptor signaling pathway (GO:0008286) is the series of molecular signals generated as a consequence of the insulin receptor binding to insulin. It is a canonical receptor tyrosine kinase (RTK) pathway that converts a hormonal cue into coordinated changes in glucose transport, metabolism, gene expression, and cell growth. Because insulin is the primary anabolic hormone, this pathway is central to whole-body metabolic homeostasis, and its dysregulation is a hallmark of insulin resistance, type 2 diabetes, and related metabolic disorders. Beyond metabolism, insulin receptor signaling intersects with growth, longevity, and cancer biology, making it a high-priority research area. Understanding its molecular architecture, regulatory feedback, and tissue-specific outputs is essential for developing targeted therapeutics and for interpreting genetic and pharmacological perturbations.
insulin receptor signaling pathway At A Glance
| GO ID | GO:0008286 |
|---|---|
| GO term | insulin receptor signaling pathway |
| Ontology | biological_process |
| Synonym | daf-2 receptor signaling pathway; insulin receptor signalling pathway |
| Definition | The series of molecular signals generated as a consequence of the insulin receptor binding to insulin. |
| Major function | Transduces insulin binding into metabolic, growth, and survival responses via RTK, PI3K-AKT, and MAPK signaling. |
| Key upstream ligand | Insulin |
| Key receptor | INSR (insulin receptor), a receptor tyrosine kinase |
| Evolutionary conservation | Conserved in metazoans; daf-2 is the C. elegans insulin receptor-like ortholog |
What Is GO:0008286?
In our own words, GO:0008286 (insulin receptor signaling pathway) is the biological process that begins when insulin binds to the insulin receptor (INSR) at the cell surface and proceeds through a defined sequence of intracellular molecular events. These events include receptor autophosphorylation, recruitment and phosphorylation of insulin receptor substrates (IRS proteins), activation of phosphatidylinositol 3-kinase (PI3K) and downstream AKT, and engagement of the Ras-MAPK cascade. The pathway ultimately alters glucose uptake, glycogen and lipid synthesis, protein synthesis, and cell survival, and it is subject to extensive feedback regulation.
Why Is insulin receptor signaling pathway Important in Cell Biology?
Insulin receptor signaling is one of the most intensively studied pathways in biology because it governs systemic glucose homeostasis and is the primary target of insulin resistance, the core defect in type 2 diabetes and metabolic syndrome. Its dysregulation also contributes to cancer progression, chemoresistance, and altered longevity, and it is a validated node for therapeutic intervention with insulin analogs, receptor agonists, and small-molecule modulators. Consequently, researchers across endocrinology, metabolism, oncology, and aging need robust experimental models to dissect pathway causality and identify new drug targets.
• Controls glucose uptake in muscle and adipose tissue and suppresses hepatic glucose production.
• Central to the pathogenesis of insulin resistance and type 2 diabetes.
• Regulates lipid and protein metabolism, linking to obesity and dyslipidemia.
• Influences cell proliferation and survival, with implications for cancer and chemoresistance.
• Modulates longevity and stress responses through conserved insulin/IGF-like signaling.
• Provides a paradigm for receptor tyrosine kinase signal transduction and feedback control.
• Target for therapeutic agonists and pathway modulators.
• Tissue-specific roles require conditional and isoform-specific models.
• Cross-talks with IGF-1 receptor and other RTKs, complicating inhibitor interpretation.
• Widely used in CRISPR screens to identify modifiers of insulin sensitivity.
What Happens During insulin receptor signaling pathway?
Insulin binding and receptor activation
In simple terms: Insulin docks onto its receptor, switching the receptor on.
The pathway initiates when insulin binds the extracellular domain of the insulin receptor (INSR), a disulfide-linked tetrameric receptor tyrosine kinase. Binding induces conformational changes that activate the intracellular kinase domains, leading to trans-autophosphorylation of tyrosine residues in the juxtamembrane and kinase domains. This autophosphorylation creates docking sites for downstream adaptor and substrate proteins, converting the receptor into an active signaling platform.
IRS recruitment and PI3K-AKT activation
In simple terms: The activated receptor tags IRS proteins, which then switch on PI3K and AKT to drive metabolic effects.
Phosphorylated INSR recruits insulin receptor substrates (IRS1, IRS2, and others) and phosphorylates them on tyrosine residues. Tyrosine-phosphorylated IRS proteins bind the p85 regulatory subunit of phosphatidylinositol 3-kinase (PIK3R1), activating the p110 catalytic subunit (PIK3CA) to generate PIP3. PIP3 recruits PDK1 and AKT to the membrane, where AKT is phosphorylated and activated; active AKT phosphorylates AS160 (TBC1D4) to promote GLUT4 translocation and glucose uptake, and phosphorylates GSK3 to stimulate glycogen synthesis.
Ras-MAPK branch
In simple terms: A second branch of the receptor uses a relay of proteins to control gene expression and cell growth.
In addition to PI3K-AKT, activated INSR recruits the adaptor GRB2 and the guanine nucleotide exchange factor SOS1, which activates Ras (HRAS, KRAS, NRAS). Ras then activates the kinase cascade RAF1 to MAP2K1/2 to MAPK1/3 (ERK1/2), which translocates to the nucleus and regulates transcription factors controlling proliferation, differentiation, and metabolism. This branch is often co-activated with PI3K-AKT and contributes to the pleiotropic effects of insulin.
Metabolic and transcriptional outputs
In simple terms: The signal changes what the cell does: it takes up sugar, stores energy, and adjusts gene activity.
Downstream of AKT and MAPK, insulin signaling promotes GLUT4 translocation to the plasma membrane in muscle and fat, increases glycogen synthesis via GSK3 inhibition, stimulates lipogenesis through SREBP1c and ACC, and enhances protein synthesis via mTORC1. It also suppresses hepatic gluconeogenesis by inhibiting FOXO1 and PGC1A. These outputs are tissue-specific and depend on the abundance of receptor isoforms and downstream effectors.
Feedback regulation and termination
In simple terms: The cell has brakes to prevent the signal from running too long.
Signaling is terminated by receptor internalization and degradation, and by negative feedback loops. For example, mTORC1 and S6K phosphorylate IRS1 on serine residues, reducing its ability to propagate insulin signals. Phosphatases such as PTP1B and lipid phosphatases like PTEN and SHIP2 also attenuate the pathway. Dysregulation of these feedback mechanisms contributes to insulin resistance.
Key Genes Involved in GO:0008286 insulin receptor signaling pathway
The following genes and proteins are core components or major modulators of the insulin receptor signaling pathway (GO:0008286).
| Gene | Major Role | Research Relevance |
|---|---|---|
| INSR | Insulin receptor tyrosine kinase; initiates signaling upon insulin binding | Primary target for knockout, point-mutation, and agonist studies |
| IRS1 | Docking protein; mediates PI3K activation | Commonly mutated in insulin resistance models |
| IRS2 | Docking protein; important in liver and beta cells | Knockout causes diabetes in mice |
| PIK3CA | Catalytic subunit of PI3K; generates PIP3 | Oncogenic mutations; target in cancer and metabolism |
| PIK3R1 | Regulatory subunit of PI3K; binds IRS | Mutations linked to insulin resistance and cancer |
| AKT1 | Serine/threonine kinase; mediates metabolic and survival signals | Key node for point-mutation and inhibitor studies |
| AKT2 | Insulin-responsive AKT isoform; regulates glucose uptake | Tissue-specific knockout models |
| TBC1D4 | AS160; AKT substrate regulating GLUT4 trafficking | Knockout impairs glucose transport |
| SLC2A4 | GLUT4 glucose transporter; mediates insulin-stimulated uptake | Overexpression and knock-in models |
| GSK3A | Glycogen synthase kinase; inhibited by AKT | Point-mutation to study glycogen synthesis |
| FOXO1 | Transcription factor inhibited by AKT; controls gluconeogenesis | Knockout and knock-in for metabolic gene regulation |
| GRB2 | Adaptor linking INSR to Ras-MAPK | Domain-specific mutants for signaling branch dissection |
| SOS1 | Guanine nucleotide exchange factor for Ras | Loss-of-function studies in MAPK branch |
| HRAS | Small GTPase activating RAF-MAPK cascade | Point-mutation models for oncogenic signaling |
| MAPK1 | ERK2; effector kinase regulating transcription | Knockout and kinase-dead knock-in |
| PTPN1 | PTP1B phosphatase; negative regulator of INSR | Knockout improves insulin sensitivity |
| PTEN | Lipid phosphatase; opposes PI3K signaling | Knockout used to amplify AKT signaling |
| daf-2 | C. elegans insulin receptor-like ortholog; regulates longevity | Model for conserved insulin/IGF signaling |
How Is insulin receptor signaling pathway Regulated?
Insulin receptor signaling is tightly regulated at multiple levels. Receptor abundance and isoform expression (IR-A vs IR-B) modulate ligand affinity and downstream output. Negative feedback via mTORC1-S6K-mediated serine phosphorylation of IRS1 desensitizes the pathway, while phosphatases such as PTP1B and lipid phosphatases PTEN and SHIP2 terminate signals. Additionally, cross-talk with IGF-1 receptor and other RTKs can bypass or amplify insulin signals, which is relevant in cancer and chemoresistance. These regulatory layers are frequently disrupted in insulin-resistant states, making them attractive targets for experimental perturbation.
insulin receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| INSR | Insulin resistance, type 2 diabetes, rare insulin receptoropathies | Knockout and point-mutation cell lines; patient-derived iPSCs |
| IRS1 | Insulin resistance, type 2 diabetes | Serine-to-alanine knock-in to block inhibitory phosphorylation |
| AKT2 | Insulin resistance, lipodystrophy | Tissue-specific knockout and kinase-dead knock-in |
| SLC2A4 | Impaired glucose uptake in diabetes | Overexpression and tagged knock-in for trafficking studies |
| daf-2 | Longevity and diapause in C. elegans | Loss-of-function mutants for lifespan assays |
Insulin resistance and type 2 diabetes
Impaired insulin receptor signaling is a central feature of insulin resistance, the hallmark of type 2 diabetes and metabolic syndrome. Defects include reduced INSR tyrosine phosphorylation, increased IRS1 serine phosphorylation, and decreased AKT activation, leading to impaired glucose uptake and increased hepatic glucose output. Experimental models with knockout or point mutations in INSR, IRS1, or AKT2 recapitulate key aspects of these disorders.
Cancer and chemoresistance
Insulin receptor signaling promotes proliferation and survival, and its hyperactivation is implicated in several cancers. IR-A isoform expression and IGF-1R cross-talk can drive mitogenic signaling and contribute to resistance to targeted therapies. CRISPR knockout of INSR or downstream nodes is used to test dependence and to identify combination strategies.
Aging and longevity
The insulin/IGF-1 signaling axis is evolutionarily linked to longevity. In C. elegans, mutations in daf-2, the insulin receptor-like gene, extend lifespan and alter diapause, establishing a conserved role for this pathway in aging. This has motivated studies of insulin signaling in age-related diseases.
From insulin receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of INSR abolish insulin-stimulated glucose uptake? | INSR knockout cell line (e.g., muscle or adipocyte) |
| Does a specific IRS1 phosphorylation site mediate feedback inhibition? | IRS1 point-mutation knock-in (serine to alanine) |
| Can a designed agonist activate INSR independently of insulin? | INSR knock-in with reporter or de novo agonist studies |
| What is the role of AKT2 in hepatic glucose production? | Liver-specific AKT2 knockout |
| How does GLUT4 trafficking respond to insulin? | SLC2A4 tagged knock-in for live imaging |
| Which genes modify insulin sensitivity in a genome-wide screen? | CRISPR library screening in insulin-responsive cells |
How to Study the insulin receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phosphorylation status of INSR, IRS1, AKT, MAPK | Validation of pathway activation/inhibition |
| Phosphoproteomics | Global phosphorylation changes | Mapping feedback and crosstalk |
| Glucose uptake assay | Insulin-stimulated glucose transport | Functional assessment of insulin sensitivity |
| CRISPR knockout screen | Gene essentiality or modifiers of insulin response | Discovery of novel pathway regulators |
| Live-cell imaging | GLUT4 translocation and AKT activity dynamics | Spatiotemporal analysis of signaling |
| Co-immunoprecipitation | Protein-protein interactions (e.g., INSR-IRS) | Mapping signaling complexes |
| RNA-seq | Transcriptional changes downstream of insulin | Identifying gene expression signatures |
| CRISPR knock-in reporter | Endogenous pathway activity | Quantitative dose-response studies |
Phosphoproteomics and Western blotting
Measuring phosphorylation of INSR, IRS1, AKT, and MAPK1/3 by Western blot or mass spectrometry provides a direct readout of pathway activation. Phosphoproteomics can quantify hundreds of sites and reveal feedback networks.
Glucose uptake assays
Radiolabeled or fluorescent glucose analogs (e.g., 2-NBDG) are used to measure insulin-stimulated glucose uptake in muscle and fat cells, a functional endpoint of the pathway.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify modifiers of insulin sensitivity and pathway output, enabling unbiased discovery of new regulators.
Live-cell imaging and biosensors
Fluorescently tagged GLUT4, AKT biosensors (e.g., AKTAR), and FRET reporters allow real-time visualization of pathway dynamics and subcellular localization.
How CRISPR Can Be Used to Study GO:0008286 insulin receptor signaling pathway
Knockout
CRISPR knockout of INSR, IRS1, AKT2, or other core genes is used to test necessity in insulin-stimulated glucose uptake, glycogen synthesis, and gene expression. Knockout cell lines provide clean backgrounds for reconstitution experiments with wild-type or mutant alleles.
Point Mutation
Point mutations (e.g., kinase-dead INSR, phosphorylation-site mutants of IRS1) allow precise dissection of catalytic activity and feedback mechanisms without confounding effects of protein loss. These models are valuable for studying insulin resistance mechanisms.
Knock-in
Knock-in of tagged alleles (e.g., GFP-GLUT4, HA-IRS1) enables visualization and biochemical isolation of endogenous proteins under native regulation. Knock-in of disease-associated mutations can model insulin receptoropathies.
Overexpression
Overexpression of wild-type or constitutively active INSR, AKT, or GLUT4 is used to amplify pathway output and study downstream effects, including oncogenic transformation. Inducible systems allow temporal control.
How EDITGENE Supports insulin receptor signaling pathway Research
Researchers studying insulin receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway output, metabolic phenotypes, or disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for insulin receptor signaling pathway research.
Frequently Asked Questions About insulin receptor signaling pathway
What is the insulin receptor signaling pathway?
It is the series of molecular signals generated when insulin binds the insulin receptor (INSR), leading to changes in glucose uptake, metabolism, and gene expression.
What is GO:0008286?
GO:0008286 is the Gene Ontology identifier for the biological process 'insulin receptor signaling pathway'.
What genes are involved in insulin receptor signaling?
Key genes include INSR, IRS1, IRS2, PIK3CA, PIK3R1, AKT1, AKT2, TBC1D4, SLC2A4, GRB2, SOS1, HRAS, MAPK1, and PTPN1.
How does insulin receptor signaling work?
Insulin binding activates INSR tyrosine kinase, which phosphorylates IRS proteins, activating PI3K-AKT and Ras-MAPK cascades to regulate metabolism and growth.
What happens when insulin receptor signaling is impaired?
Impaired signaling causes insulin resistance, reduced glucose uptake, increased hepatic glucose output, and contributes to type 2 diabetes.
Is the insulin receptor signaling pathway conserved?
Yes, it is conserved across metazoans; the C. elegans daf-2 gene is an insulin receptor-like ortholog that regulates longevity.
How can I study insulin receptor signaling in the lab?
Common methods include Western blot for phosphorylation, glucose uptake assays, phosphoproteomics, CRISPR screens, and live-cell imaging.
What are the insulin receptor isoforms?
The insulin receptor has two main isoforms, IR-A and IR-B, which differ in ligand affinity and signaling output and are implicated in cancer.
Can CRISPR be used to study insulin receptor signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect pathway gene function.
What diseases are linked to insulin receptor signaling?
Type 2 diabetes, insulin resistance, metabolic syndrome, and certain cancers are linked to dysregulated insulin receptor signaling.
Conclusion
The insulin receptor signaling pathway (GO:0008286) is a fundamental biological process that translates insulin binding into metabolic, growth, and survival responses. Its core components and regulatory mechanisms are well defined, and its dysfunction is central to major human diseases including type 2 diabetes and cancer. Continued research using precise CRISPR models and functional genomics will clarify remaining questions about tissue-specific signaling and therapeutic targeting.
References
- 1. Boucher J et al.. 2014. Insulin receptor signaling in normal and insulin-resistant states.. Cold Spring Harb Perspect Biol 6(1) PMID: 24384568
- 2. Lee J et al.. 1994. The insulin receptor: structure, function, and signaling.. Am J Physiol 266(2 Pt 1):C319-34 PMID: 8141246
- 3. Wang X et al.. 2025. Tuning insulin receptor signaling using de novo-designed agonists.. Mol Cell 85(21):4064-4081.e9 PMID: 41086805
- 4. Baghaie L et al.. 2023. Insulin Receptor Signaling in Health and Disease.. Biomolecules 13(5) PMID: 37238677
- 5. Zhao X et al.. 2023. The crucial role and mechanism of insulin resistance in metabolic disease.. Front Endocrinol (Lausanne) 14:1149239 PMID: 37056675
- 6. James DE et al.. 2021. The aetiology and molecular landscape of insulin resistance.. Nat Rev Mol Cell Biol 22(11):751-771 PMID: 34285405
- 7. Kimura KD et al.. 1997. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans.. Science 277(5328):942-6 PMID: 9252323
- 8. Galal MA et al.. 2023. Insulin Receptor Isoforms and Insulin Growth Factor-like Receptors: Implications in Cell Signaling, Carcinogenesis, and Chemoresistance.. Int J Mol Sci 24(19) PMID: 37834454
